How PD-1 receptor occupancy assay supports PD-1 therapies

IDT CRISPR-based therapies - new Alt-R™ HDR Enhancer Protein 1. Excellent Performance: Consistently increases HDR rates up to 2-fold across diverse and challenging cell types like iPSCs, and HSPCs. 2. Unmatched Precision: Enhances editing efficiency without increasing off-target effects, translocation rates, or compromising cell viability. 3. Seamless Integration: Designed to fit effortlessly into your existing workflows, providing a smooth transition from discovery to the clinic with both RUO and CGMP (coming soon) options available. 4. Accelerated Timelines: Boosts edited cell yields, shortening development cycles, and fast-tracking your therapeutic research programs. Explore how can accelerate your CRISPR therapeutics project https://lnkd.in/dp6zZPxa

New findings in eosinophilic COPD: Did you know that biologics targeting type 2 inflammation show the most promise for the condition? New analysis has found that certain drugs can reduce flare-ups and improve lung function when guided by biomarkers. Find out how: https://hubs.la/Q03KZCRJ0

A new article in Healio spotlights Phase 1 results for GB-0895, our #AI-engineered antibody that targets TSLP, a key driver of airway inflammation in #asthma. The piece highlights data showing six-month pharmacology following a single dose and perspectives from lead investigator Professor Dave Singh, MD, on how long-acting biologics could help reduce treatment burden for patients with severe asthma. External coverage like this illustrates how the ability to program biology is moving from scientific concept to clinical reality, helping define what’s next in respiratory care. Read the full article → https://lnkd.in/eSbJWAZF #ERS2025 | #GenerativeAI

BREAKING NEWS - Sanofi’s targeted alpha therapy demonstrates strong efficacy in Phase II trial for neuroendocrine tumours Sanofi and Orano Med have reported the clinical results from their targeted alpha therapy using lead-212. Their candidate, AlphaMedix™ (212Pb-DOTAMTATE), met all primary endpoints in the Phase II study: Achieved all primary efficacy endpoints (ORR, safety) Improved progression-free and overall survival outcomes Demonstrated a manageable and consistent safety profile AlphaMedix™ applies the precision of Targeted Alpha Therapy (TAT), using the lead-212 isotope to deliver highly potent, short-range alpha radiation directly to tumour cells. This approach could offer a potential alternative to existing peptide receptor radionuclide therapies (PRRTs) for patients with gastroenteropancreatic neuroendocrine tumours. #pharma #business #drjojo ---------- Hi! I am Joanna, and my friends call me Dr Jojo 🌸 𝐈 𝐡𝐞𝐥𝐩 𝐬𝐭𝐚𝐫𝐭𝐮𝐩𝐬 𝐚𝐧𝐝 𝐞𝐧𝐭𝐫𝐞𝐩𝐫𝐞𝐧𝐞𝐮𝐫𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐭𝐡𝐞𝐢𝐫 𝐯𝐚𝐥𝐮𝐞 𝐚𝐧𝐝 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 🔔 Follow for insights ♻️ Share if you find it interesting 📩 Book a consultation to grow your business and generate leads

🧬 Trimerbodies represent a new generation of therapeutic proteins with multivalent and multispecific capabilities. ⚙️ They are built by combining antigen-binding domains with the collagen trimerization domain. 🚀 This proprietary technology allows the fast development of novel biologics with potential applications across diverse diseases. 🔬 Thanks to their variable size, remarkable stability, and strong antigen-binding properties, Trimerbodies stand out as promising candidates for next-generation treatments. #SolidTumours #NextGenAntibodies #Immunotherapy #TrimerbodyPharma #OncologyInnovation #CancerResearch

BIO-PHARMA: AstraZeneca India has received approval from the Central Drugs Standard Control Organisation to import, market, and distribute Trastuzumab Deruxtecan (100mg/5mL vial lyophilized powder for concentrate for solution for infusion) for an additional indication in India. More details: https://lnkd.in/dFFbVPGj Central Drugs Standard Control Organization #CDSCO #trastuzumab #deruxtecan #lyophilizedpowder #antibody #biovoicenews

Advance Your ADC Research - Organoids Vs. Traditional Models Unlock insights into ADC development with HUB Organoids’ factsheet on patient-derived organoids. Discover how advanced 3D tumour models are transforming preclinical testing and supporting safer, more effective antibody-drug conjugates. What you’ll learn: - How organoids outperform traditional preclinical models for ADCs - Strategies for evaluating efficacy, safety, and biomarker discovery - Real-world case studies for optimising drug development decisions - Download to advance your ADC research with cutting-edge, patient-relevant data Download Factsheet https://lnkd.in/ebT9PQmf Follow DDW; Business insights for the global scientific community Brought to you by HUB Organoids #Organoids #DrugDiscovery #DrugDevelopment Merck Group, Merck Life Science

We released a preprint analyzing our Therapeutic Antibody Database, combining automated and manual mining of clinical trial data. The resource includes 1,109 therapeutics and 1,120 immunogenicity-focused trials across 4,306 cohorts, yielding nearly 10,500 measurements. This dataset highlights how antibody design, prediction methods, and clinical context collectively shape immunogenicity. Molecular data alone cannot predict anti-drug antibody (ADA) responses; incorporating clinical factors is essential. In short, integrating molecular and clinical insights is key to improving immunogenicity prediction and guiding smarter therapeutic development. Paper: https://lnkd.in/djC8JXXM Database: https://lnkd.in/dzrvvqQH #antibody #database #therapeutics

🔬 Precision Medicine in IBD: The Role of Diagnostics in the Era of IL-23 Inhibitors The treatment landscape for ulcerative colitis and Crohn’s disease continues to evolve rapidly, with biologics targeting TNF, integrins, IL-12/23, and now IL-23 transforming clinical outcomes. Among the latest innovations, guselkumab—a selective IL-23p19 inhibitor—has demonstrated encouraging efficacy in both UC and Crohn’s, offering subcutaneous and IV induction options recently approved by the FDA and EMA. But as biologic options expand, the real challenge for clinicians lies in precision monitoring: 1️⃣ Determining which patients are most likely to respond, 2️⃣ Measuring treatment effectiveness early, and 3️⃣ Differentiating between mechanistic failure and subtherapeutic exposure. That’s where advanced laboratory testing becomes essential. Pharmacokinetic and immunogenicity assays, molecular profiling, and inflammation biomarkers can provide actionable insights that guide therapy adjustments—ensuring that each patient receives the right treatment, at the right time. At Mayo Clinic Laboratories, our focus is on empowering gastroenterologists with high-complexity testing solutions to support informed biologic management—from initial selection to ongoing monitoring. 🧠 Informed decisions. Personalized therapy. Better outcomes. #IBD #UlcerativeColitis #CrohnsDisease #PrecisionMedicine #IL23 #Biologics #Diagnostics #MayoClinicLabs #Gastroenterology #ClinicalInnovation

The days of blockbuster, one-size-fits-all drugs are officially over. The hyper-targeted future of biopharma is here, and it's driven by the incredible convergence of Precision Medicine and Rare Disease research. The numbers are too massive to ignore: 📈 38%: That's the percentage of all newly approved FDA therapies in 2024 classified as Precision Medicine. This is now the default for innovation. 💰 $242.5 Billion: The estimated size of the global Rare Disease therapeutics market in 2025—a segment now synonymous with targeted development. But the real game-changer? The FDA just rolled out the Rare Disease Evidence Principles (RDEP). This new framework fundamentally changes the calculus for developing treatments for patient populations under 1,000. It offers predictability and speed where there was once only scientific and regulatory ambiguity. Our latest piece digs into the story. Read Article: https://lnkd.in/gg64i9UF Learn more at healthcarein.org. Follow Healthcare Insights for key coverage of the biopharma and healthcare sectors, and subscribe to our newsletter for the latest. #healthcare #biotech #biopharma #fda #medicine